Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
Although considerable progress has been made in basic pharmacogenetic research, less has been demonstrated in the application of pharmacogenetics (PGx)-based diagnostics to drug development and in clinical practice. There are drugs that are currently used in the clinic for which individualized therapy could be beneficial based on PGx data. However, specific, actionable recommendations on how to implement individualized therapy--particularly with respect to dosage--still have to be developed. Moreover, to apply PGx efficiently in clinical drug development, and later in drug therapy, study designs and the generation and handling of PGx data need to become more standardized. Here, we argue for the development of concise guidelines for implementation of PGx analyses in drug development and therapy.
Kirchheiner
Julia
J
Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Köln, Germany. julia.kirchheiner@uk-koeln.de
Fuhr
Uwe
U
Brockmöller
Jürgen
J
D002986:Clinical Trials as Topic / Q000145:classification / Q000379:methods; D004345:Drug Industry / Q000379:methods / Q000639:trends; D004358:Drug Therapy / Q000379:methods / Q000639:trends*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods / Q000639:trends*; D010818:Practice Patterns, Physicians' / Q000639:trends*; D009626:Terminology as Topic